%0 Journal Article
%A Gambichler, Thilo
%A Hyun, Julia
%A Oellig, Frank
%A Becker, Jürgen C
%A Kreuter, Alexander
%T Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review.
%J Journal der Deutschen Dermatologischen Gesellschaft
%V 23
%N 3
%@ 1610-0379
%C Berlin
%I Wiley-Blackwell
%M DKFZ-2025-00507
%P ddg.15648
%D 2025
%Z 303-308 / Mini-review
%X Patients with xeroderma pigmentosum (XP) frequently develop skin cancers early in life, including cutaneous squamous cell carcinoma (cSCC). The median age of death is 32 years and 60
%K Humans
%K Xeroderma Pigmentosum: complications
%K Xeroderma Pigmentosum: drug therapy
%K Male
%K Child
%K Skin Neoplasms: drug therapy
%K Skin Neoplasms: pathology
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: adverse effects
%K Carcinoma, Squamous Cell: drug therapy
%K Carcinoma, Squamous Cell: pathology
%K Antibodies, Monoclonal, Humanized: therapeutic use
%K Antibodies, Monoclonal, Humanized: adverse effects
%K Lymphatic Metastasis: pathology
%K DNA repair defects (Other)
%K cemiplimab (Other)
%K childhood (Other)
%K genodermatoses (Other)
%K geno‐photodermatoses (Other)
%K keratoacanthoma (Other)
%K nivolumab (Other)
%K pembrolizumab (Other)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K cemiplimab (NLM Chemicals)
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40052589
%2 pmc:PMC11886998
%R 10.1111/ddg.15648
%U https://inrepo02.dkfz.de/record/299566